Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16984323 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL19663832 | 0.79 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL13934654 | 0.78 | LMNA (0.47) | SMN1; SMN2KDM4EGAAHPGDLMNA | |
| SCHEMBL18157071 | 0.78 | KDM4E (0.39) | SMN1; SMN2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL22854054 | 0.77 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL12269670 | 0.75 | — | — | |
| SCHEMBL17740185 | 0.75 | FAAH (0.43) | SMN1; SMN2ALDH1A1KDM4EGAAHPGD | |
| SCHEMBL6980315 | 0.75 | LMNA (0.41) | SMN1; SMN2ALDH1A1GAAHPGDLMNA | |
| SCHEMBL24798835 | 0.75 | KDM4E (0.33) | SMN1; SMN2ALDH1A1KDM4EHPGDBCHE | |
| SCHEMBL6980204 | 0.74 | GAA (0.44) | ALDH1A1KDM4EGAALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024064771-A1 | ANTI-CD45-IGN ANTIBODY DRUG CONJUGATES AND USES THEREOF | VOR BIOPHARMA INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2020216947-A1 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219959-A1 | ANTI-CD45 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219775-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219964-A1 | CONDITIONING METHODS FOR GENE THERAPY | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219774-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020023556-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023559-A1 | USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023561-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019173780-A2 | ANTI-CD252 ANTIBODIES, CONJUGATES, AND METHODS OF USE | Magenta Therapeutics, Inc. (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019142147-A2 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD134+ CELLS | Magenta Therapeutics, Inc. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20170360954-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CRISPR THERAPEUTICS AG (CH) | 2017-12-21 | — | — | US | disclosed |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | AGENSYS, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360954-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CD2, CD47, SIGLEC7 | SMN1; SMN2 2262/4885ALDH1A1 361/4885KDM4E 3636/4885 |
| US-20150218220-A1 | AMATOXIN DERIVATIVES AND CELL-PERMEABLE CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | SMN1; SMN2 1919/4885ALDH1A1 2698/4885KDM4E 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.